The Q1 update from PIQ was a pretty standard affair, providing a summary of the already known items previously released over the quarter along with flat revenue from the analytical services team.
Cash outflows were $1.16m and on par with previous quarters. With $4.4m in the bank and $1.2m in R&D rebates expected this quarter, the company has about a year of runway at current operations. That may change if there is the need to ramp up manufacturing of test kits.
The main takeaway from this announcement is that the company has reaffirmed that Promarker D sales are expected in Italy this Quarter. This has been previously announced and delayed, so one would have to assume that PIQ is reasonably confident of being able to achieve this milestone for them to put a timeline on it. The big question is how commercially significant will these be?
Other upcoming items to watch:
- FDA approval pathway review is underway, a fast turn around on this would be nice but timing is a bit of an unknown.
- Submission of TGA application for Promarker D
- Prelim results from Endometriosis biomarker validation study (Q3). Any significant results on this will be a positive as this is a market with an unmet need.
- Complete transfer of manufacturing to Biotem (Q3) as this will impact the commercial pathway for Promarker D sales in Israel.
- There were hints at further markets opening up, it would be a bonus if one of these were announced this quarter, however I don’t expect anything on that front until well into next year.
Disclosure: Held